Open Access

Erratum to: Combined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in rats

  • Manpreet Kaur1,
  • Shilpi Sachdeva1,
  • Onkar Bedi1,
  • Tavleen Kaur1 and
  • Puneet Kumar1Email author
Journal of Diabetes & Metabolic Disorders201514:80

DOI: 10.1186/s40200-015-0212-8

Received: 7 October 2015

Accepted: 8 October 2015

Published: 22 October 2015

The original article was published in Journal of Diabetes & Metabolic Disorders 2015 14:63

The original version of this article [1] unfortunately contained mistakes to the figure legends and was missing Figure 7 (Fig. 1 here). The corrected legends are as follows:

Fig. 1 Experimental Protocol design.

Fig. 2 Effect of NaHS on blood glucose level in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 3 Effect of NaHS and losartan on Lipid Peroxidation in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 4 Effect of NaHS and losartan on Reduced Glutathione in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 5 Effect of NaHS and losartan on Nitrite in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

Fig. 6 Effect of NaHS and losartan on MABP in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.

The missing figure can be found below, with the correct figure legend:
Fig. 1

Hemotoxylin-Eosin stained longitudinal section of kidneys (10×). a Normal control, b STZ treated group (45), c NaHS (30), d DL-p (10) + NaHS (30), e LOS, f NaHS (10) + Losartan (5)

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Pharmacology Division, Department of Pharmacology, ISF College of Pharmacy

Reference

  1. Kaur M, Sachdeva S, Bedi O, Kaur T, Kumar P. Combined effect of hydroden sulphide donor and losartan in experimental diabetic nephropathy in rats. J Diabetes Metab Disord. 2015;14:63. doi:10.1186/s40200-015-0185-7.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Kaur et al. 2015

Advertisement